Affibody Molecules in Biotechnological and Medical Applications

Trends in Biotechnology

Volumn 35, Issue 8, 2017, Pages 691-712

  Ståhl, Stefan ^a   Gräslund, Torbjörn ^a   Eriksson Karlström, Amelie ^a   Frejd, Fredrik Y ^b,c   Nygren, Per Åke ^a   Löfblom, John ^a  

^a ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c Affibody AB   (Sweden)

Author keywords

affibody; affinity protein; alternative scaffolds; biologicals; molecular imaging; next generation biotherapeutics; targeted therapy

Indexed keywords

BIOTECHNOLOGY; COVALENT BONDS; DIAGNOSIS; MEDICAL APPLICATIONS; MOLECULAR IMAGING; NEURODEGENERATIVE DISEASES; PATHOLOGY; PATIENT TREATMENT; PROTEINS; SCAFFOLDS (BIOLOGY); SULFUR COMPOUNDS;

AFFIBODY; BIOLOGICALS; BIOTECHNOLOGICAL APPLICATIONS; BIOTHERAPEUTICS; CLINICAL DEVELOPMENT; PEPTIDE AGGREGATION; PROTEIN INTERACTION; TARGETED THERAPY;

MOLECULES;

AFFIBODY MOLECULE; NANOPARTICLE; PEPTIDES AND PROTEINS; TRACER; UNCLASSIFIED DRUG; HYBRID PROTEIN;

BIOTECHNOLOGY; CANCER SURGERY; DRUG DELIVERY SYSTEM; DRUG SELECTIVITY; FLUORESCENCE; HUMAN; IN VITRO STUDY; INFLAMMATION; MOLECULAR IMAGING; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; RECEPTOR BLOCKING; REVIEW; ANIMAL; DEGENERATIVE DISEASE; DRUG EFFECTS; METABOLISM; NEOPLASM; PATHOLOGY; PROCEDURES; SIGNAL TRANSDUCTION; TRENDS;

ANIMALS; BIOTECHNOLOGY; HUMANS; INFLAMMATION; NEOPLASMS; NEURODEGENERATIVE DISEASES; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION;

EID: 85019227020     PISSN: 01677799     EISSN: 18793096     Source Type: Journal    
DOI: 10.1016/j.tibtech.2017.04.007     Document Type: Review

References (152)

1. Gebauer, M., Skerra, A., Engineered protein scaffolds as next-generation antibody therapeutics. Curr. Opin. Chem. Biol. 13 (2009), 245–255.
2. Löfblom, J., et al. Non-immunoglobulin based protein scaffolds. Curr. Opin. Biotechnol. 22 (2011), 843–848.
3. Nord, K., et al. A combinatorial library of an alpha-helical bacterial receptor domain. Protein Eng. 8 (1995), 601–608.
4. Nord, K., et al. Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nat. Biotechnol. 15 (1997), 772–777.
5. Fedorova, A., et al. The development of peptide-based tools for the analysis of angiogenesis. Chem. Biol. 18 (2011), 839–845.
6. Xue, X., et al. Generation of affibody molecules specific for HPV16 E7 recognition. Oncotarget 7 (2016), 73995–74005.
7. Wang, H., et al. LOVTRAP: an optogenetic system for photoinduced protein dissociation. Nat. Methods 13 (2016), 755–758.
8. Löfblom, J., Bacterial display in combinatorial protein engineering. Biotechnol. J. 6 (2011), 1115–1129.
9. Kronqvist, N., et al. A novel affinity protein selection system based on staphylococcal cell surface display and flow cytometry. Protein Eng. Des. Sel. 21 (2008), 247–255.
10. Lofdahl, P.A., et al. Selection of TNF-alpha binding affibody molecules using a beta-lactamase protein fragment complementation assay. Nat. Biotechnol. 26 (2009), 251–259.
11. Grimm, S., et al. Ribosome display selection of a murine IgG(1) Fab binding affibody molecule allowing species selective recovery of monoclonal antibodies. Mol. Biotechnol. 48 (2011), 263–276.
12. Lindberg, H., et al. Flow-cytometric screening of aggregation-inhibitors using a fluorescence-assisted intracellular method. Biotechnol. J., 2016, 10.1002/biot.201600364 Published online December 1, 2016.
13. Kronqvist, N., et al. Staphylococcal surface display in combinatorial protein engineering and epitope mapping of antibodies. Recent Pat. Biotechnol. 4 (2010), 171–182.
14. Orlova, A., et al. Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 66 (2006), 4339–4348.
15. Malm, M., et al. Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification. PLoS One, 8, 2013, e62791.
16. Lindberg, H., et al. A truncated and dimeric format of an affibody library on bacteria enables FACS-mediated isolation of amyloid-beta aggregation inhibitors with subnanomolar affinity. Biotechnol. J. 10 (2015), 1707–1718.
17. Fleetwood, F., et al. Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic affibody molecules results in dramatically improved affinity. Sci. Rep., 4, 2014, 7518.
18. Arunachalam, T.S., Mixed oligonucleotides for random mutagenesis: best way of making them. Org. Biomol. Chem. 10 (2012), 4641–4650.
19. Feldwisch, J., et al. Design of an optimized scaffold for affibody molecules. J. Mol. Biol. 398 (2010), 232–247.
20. Lindgren, J., et al. A native chemical ligation approach for combinatorial assembly of affibody molecules. Chembiochem 13 (2012), 1024–1031.
21. Perols, A., et al. Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules. Bioconjug. Chem. 23 (2012), 1661–1770.
22. Nygren, P.Å., Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J. 275 (2008), 2668–2676.
23. Löfblom, J., et al. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett. 584 (2010), 2670–2680.
24. Tolmachev, V., et al. Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. Lancet Oncol. 11 (2010), 992–1000.
25. Wallberg, H., Stahl, S., Design and evaluation of radiolabeled tracers for tumor imaging. Biotechnol. Appl. Biochem. 60 (2013), 365–383.
26. Andersson, K.G., et al. Feasibility of imaging of epidermal growth factor receptor expression with ZEGFR:2377 affibody molecule labeled with 99mTc using a peptide-based cysteine-containing chelator. Int. J. Oncol. 49 (2016), 2285–2293.
27. Wallberg, H., et al. Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties. J. Nucl. Med. 52 (2011), 461–469.
28. Westerlund, K., et al. Increasing the net negative charge by replacement of DOTA chelator with DOTAGA improves the biodistribution of radiolabeled second-generation synthetic affibody molecules. Mol. Pharm. 13 (2016), 1668–1678.
29. Sorensen, J., et al. First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule. J. Nucl. Med. 55 (2014), 730–735.
30. Choi, J.W., et al. Two-photon tracer for human epidermal growth factor receptor-2: detection of breast cancer in a live tissue. Anal. Chem. 88 (2016), 9412–9418.
31. Cheng, Q., et al. Preclinical PET imaging of EGFR levels: pairing a targeting with a non-targeting Sel-tagged affibody-based tracer to estimate the specific uptake. EJNMMI Res., 6, 2016, 58.
32. Garousi, J., et al. PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR:2377 affibody molecules. Int. J. Oncol. 48 (2016), 1325–1332.
33. Rosestedt, M., et al. Affibody-mediated PET imaging of HER3 expression in malignant tumours. Sci. Rep., 5, 2015, 15226.
34. Strand, J., et al. Gallium-68-labeled affibody molecule for PET imaging of PDGFRbeta expression in vivo. Mol. Pharm. 11 (2014), 3957–3964.
35. Mitran, B., et al. Evaluation of 99mTc-Z IGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression. Amino Acids 47 (2015), 303–315.
36. Garousi, J., et al. Comparative evaluation of affibody molecules for radionuclide imaging of in vivo expression of carbonic anhydrase IX. Mol. Pharm. 13 (2016), 3676–3687.
37. Sorensen, J., et al. Measuring HER2-receptor expression in metastatic breast cancer using [(68)Ga]ABY-025 affibody PET/CT. Theranostics 6 (2016), 262–271.
38. Sandstrom, M., et al. Biodistribution and radiation dosimetry of the anti-HER2 affibody molecule 68Ga-ABY-025 in breast cancer patients. J. Nucl. Med. 57 (2016), 867–871.
39. Baum, R.P., et al. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. J. Nucl. Med. 51 (2010), 892–897.
40. Velikyan, I., et al. Good manufacturing practice production of [(68)Ga]Ga-ABY-025 for HER2 specific breast cancer imaging. Am. J. Nucl. Med. Mol. Imaging 6 (2016), 135–153.
41. Terwisscha van Scheltinga, A.G., et al. ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody (8)(9)Zr-RG7116. MAbs 6 (2014), 1051–1058.
42. Razumienko, E.J., et al. Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates. J. Nucl. Med. 53 (2012), 1943–1950.
43. Da Pieve, C., et al. Efficient [(18)F]AlF radiolabeling of ZHER3:8698 affibody molecule for imaging of HER3 positive tumors. Bioconjug. Chem. 27 (2016), 1839–1849.
44. Honarvar, H., et al. Evaluation of the first 44Sc-labeled affibody molecule for imaging of HER2-expressing tumors. Nucl. Med. Biol. 45 (2017), 15–21.
45. Hofstrom, C., et al. HAHAHA, HEHEHE, HIHIHI, or HKHKHK: influence of position and composition of histidine containing tags on biodistribution of [(99m)Tc(CO)3](+)-labeled affibody molecules. J. Med. Chem. 56 (2013), 4966–4974.
46. Wallberg, H., et al. HER2-positive tumors imaged within 1 hour using a site-specifically 11C-labeled Sel-tagged affibody molecule. J. Nucl. Med. 53 (2012), 1446–1453.
47. Zhao, N., et al. Small-protein-stabilized semiconductor nanoprobe for targeted imaging of cancer cells. Chembiochem 17 (2016), 1202–1206.
48. Antaris, A.L., et al. A small-molecule dye for NIR-II imaging. Nat. Mater. 15 (2016), 235–242.
49. Satpathy, M., et al. Optical imaging of ovarian cancer using HER-2 affibody conjugated nanoparticles. Methods Mol. Biol. 1219 (2015), 171–185.
50. Vargo, K.B., et al. Superparamagnetic iron oxide nanoparticle micelles stabilized by recombinant oleosin for targeted magnetic resonance imaging. Small 11 (2015), 1409–1413.
51. Wang, Y., et al. A novel affibody bioconjugate for dual-modality imaging of ovarian cancer. Chem. Commun. (Camb) 50 (2014), 12832–12835.
52. Yang, M., et al. Affibody modified and radiolabeled gold-iron oxide hetero-nanostructures for tumor PET, optical and MR imaging. Biomaterials 34 (2013), 2796–2806.
53. Pogue, B.W., et al. Vision 20/20: Molecular-guided surgical oncology based upon tumor metabolism or immunologic phenotype: technological pathways for point of care imaging and intervention. Med. Phys., 43, 2016, 3143.
54. de Souza, A.L., et al. Fluorescent affibody molecule administered In vivo at a microdose level labels egfr expressing glioma tumor regions. Mol. Imaging Biol. 19 (2017), 41–48.
55. Samkoe, K.S., et al. Toxicity and pharmacokinetic profile for single-dose injection of ABY-029: a fluorescent anti-EGFR synthetic affibody molecule for human use. Mol. Imaging Biol., 2016, 10.1007/s11307-016-1033-y Published online December 1, 2016.
56. Elliott, J.T., et al. Simultaneous in vivo fluorescent markers for perfusion, protoporphyrin metabolism and EGFR expression for optically guided identification of orthotopic glioma. Clin. Cancer Res. 23 (2017), 2203–2212.
57. Sexton, K., et al. Fluorescent affibody peptide penetration in glioma margin is superior to full antibody. PLoS One, 8, 2013, e60390.
58. Malm, M., et al. Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds. MAbs 8 (2016), 1195–1209.
59. Kronqvist, N., et al. Combining phage and staphylococcal surface display for generation of ErbB3-specific affibody molecules. Protein Eng. Des. Sel. 24 (2011), 385–396.
60. Malm, M., et al. Engineering of a bispecific affibody molecule towards HER2 and HER3 by addition of an albumin-binding domain allows for affinity purification and in vivo half-life extension. Biotechnol. J. 9 (2014), 1215–1222.
61. Schardt, J.S., et al. Engineered multivalency enhances affibody-based HER3 inhibition and downregulation in cancer cells. Mol. Pharm. 14 (2017), 1047–1056.
62. Malm, M., et al. Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification. PLoS One, 8, 2013, e62791.
63. Bass, T.Z., et al. In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct. Sci. Rep., 7, 2017, 43118.
64. LaFleur, D., et al. Monoclonal antibody therapeutics with up to five specificities: functional enhancement through fusion of target-specific peptides. MAbs 6 (2013), 208–218.
65. Fleetwood, F., et al. Novel affinity binders for neutralization of vascular endothelial growth factor (VEGF) signaling. Cell. Mol. Life Sci. 73 (2016), 1671–1683.
66. Lindborg, M., et al. Engineered high-affinity affibody molecules targeting platelet-derived growth factor receptor beta in vivo. J. Mol. Biol. 407 (2011), 298–315.
67. Li, J., et al. Selection of affibody molecules to the ligand-binding site of the insulin-like growth factor-1 receptor. Biotechnol. Appl. Biochem. 55 (2010), 99–109.
68. Yu, F., et al. An affibody-adalimumab hybrid blocks combined IL-6 and TNF-triggered serum amyloid A secretion in vivo. MAbs 6 (2014), 1598–1607.
69. Jonsson, A., et al. Generation of tumour-necrosis-factor-alpha-specific affibody molecules capable of blocking receptor binding in vitro. Biotechnol. Appl. Biochem. 54 (2009), 93–103.
70. Berlec, A., et al. Dextran sulphate sodium colitis in C57BL/6J mice is alleviated by Lactococcus lactis and worsened by the neutralization of tumor necrosis factor alpha. Int. Immunopharmacol. 43 (2017), 219–226.
71. Gordon, K.B., et al. Phase 3 trials of Ixekizumab in moderate-to-severe plaque psoriasis. N. Engl. J. Med. 375 (2016), 345–356.
72. Gottlieb, A.B., et al. Secukinumab self-administration by prefilled syringe maintains reduction of plaque psoriasis severity over 52 weeks: results of the FEATURE trial. J. Drugs Dermatol. 15 (2016), 1226–1234.
73. Berglund, M.M., Stromberg, P., The clinical potential of affibody-based inhibitors of C5 for therapeutic complement disruption. Expert Rev. Proteom. 13 (2016), 241–243.
74. Grimm, S., et al. Selection and characterisation of affibody molecules inhibiting the interaction between Ras and Raf in vitro. N. Biotechnol. 27 (2010), 766–773.
75. Grimm, S., et al. Monitored whole gene in vitro evolution of an anti-hRaf-1 affibody molecule towards increased binding affinity. N. Biotechnol. 29 (2012), 534–542.
76. Shibasaki, S., et al. Inhibitory effects of H-Ras/Raf-1-binding affibody molecules on synovial cell function. AMB Express, 4, 2014, 82.
77. Liao, X., et al. Delivery of antibody mimics into mammalian cells via anthrax toxin protective antigen. Chembiochem 15 (2014), 2458–2466.
78. Gronwall, C., et al. Selection and characterization of affibody ligands binding to Alzheimer amyloid beta peptides. J. Biotechnol. 128 (2007), 162–183.
79. Hoyer, W., et al. Stabilization of a beta-hairpin in monomeric Alzheimer's amyloid-beta peptide inhibits amyloid formation. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 5099–5104.
80. Luheshi, L.M., et al. Sequestration of the Abeta peptide prevents toxicity and promotes degradation in vivo. PLoS Biol., 8, 2010, e1000334.
81. De Genst, E., Muyldermans, S., Development of a high affinity affibody-derived protein against amyloid beta-peptide for future Alzheimer's disease therapy. Biotechnol. J. 10 (2015), 1668–1669.
82. Boutajangout, A., et al. An affibody to monomeric abeta as a novel therapeutic approach for Alzheimer's disease pathology. Alzheimers Dement. J. Alzheimers Assoc. 12 (2016), P835–P836.
83. Gruning, C.S., et al. Alternative conformations of the Tau repeat domain in complex with an engineered binding protein. J. Biol. Chem. 289 (2014), 23209–23218.
84. Mirecka, E.A., et al. Sequestration of a beta-hairpin for control of alpha-synuclein aggregation. Angew. Chem. Int. Ed. Engl. 53 (2014), 4227–4230.
85. Gauhar, A., et al. Impact of subunit linkages in an engineered homodimeric binding protein to alpha-synuclein. Protein Eng. Des. Sel. 27 (2014), 473–479.
86. Mirecka, E.A., et al. Engineered aggregation inhibitor fusion for production of highly amyloidogenic human islet amyloid polypeptide. J. Biotechnol. 191 (2014), 221–227.
87. Mirecka, E.A., et al. Beta-hairpin of islet amyloid polypeptide bound to an aggregation inhibitor. Sci. Rep., 6, 2016, 33474.
88. Zielinski, R., et al. Affitoxin – a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors. J. Immunother. 32 (2009), 817–825.
89. Zielinski, R., et al. HER2-affitoxin: a potent therapeutic agent for the treatment of HER2-overexpressing tumors. Clin. Cancer Res. 17 (2011), 5071–5081.
90. Liu, H., et al. Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin ZHER2:2891-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domain. Int. J. Oncol. 47 (2015), 601–609.
91. Guo, R., et al. Fusion of an albumin-binding domain extends the half-life of immunotoxins. Int. J. Pharm. 511 (2016), 538–549.
92. Altai, M., et al. Influence of molecular design on biodistribution and targeting properties of an affibody-fused HER2-recognising anticancer toxin. Int. J. Oncol. 49 (2016), 1185–1194.
93. Mazor, R., et al. Immunogenicity of therapeutic recombinant immunotoxins. Immunol. Rev. 270 (2016), 152–164.
94. Weldon, J.E., et al. Designing the furin-cleavable linker in recombinant immunotoxins based on Pseudomonas exotoxin A. Bioconjug. Chem. 26 (2015), 1120–1128.
95. Guo, R., et al. HER2-targeted immunotoxins with low nonspecific toxicity and immunogenicity. Biochem. Biophys. Res. Commun. 475 (2016), 93–99.
96. Alewine, C., et al. Advances in anticancer immunotoxin therapy. Oncologist 20 (2015), 176–185.
97. McCluskey, A.J., Collier, R.J., Receptor-directed chimeric toxins created by sortase-mediated protein fusion. Mol. Cancer Ther. 12 (2013), 2273–2281.
98. McCluskey, A.J., et al. Targeting HER2-positive cancer cells with receptor-redirected anthrax protective antigen. Mol. Oncol. 7 (2013), 440–451.
99. Zahaf, N.I., et al. Targeted delivery of an ADP-ribosylating bacterial toxin into cancer cells. Sci. Rep., 7, 2017, 41252.
100. Sochaj-Gregorczyk, A.M., A novel affibody-auristatin e conjugate with a potent and selective activity against HER2+ cell lines. J. Immunother. 39 (2016), 223–232.
101. Serwotka-Suszczak, A.M., et al. A conjugate based on anti-HER2 diaffibody and Auristatin E targets HER 2-positive cancer cells. Int. J. Mol. Sci., 2017, 18.
102. Orlova, A., et al. (186)Re-maSGS-Z (HER2:342), a potential affibody conjugate for systemic therapy of HER2-expressing tumours. Eur. J. Nucl. Med. Mol. Imaging 37 (2010), 260–269.
103. Altai, M., et al. Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with (188)Re. Eur. J. Med. Chem. 87 (2014), 519–528.
104. Tolmachev, V., et al. Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding affibody molecules. Eur. J. Nucl. Med. Mol. Imaging 36 (2009), 692–701.
105. Strand, J., et al. Site-specific radioiodination of HER2-targeting affibody molecules using 4-Iodophenethylmaleimide decreases renal uptake of radioactivity. ChemistryOpen 4 (2015), 174–182.
106. Dar, G.H., et al. Conformation-dependent binding and tumor-targeted delivery of siRNA by a designed TRBP2: affibody fusion protein. Nanomedicine 11 (2015), 1455–1466.
107. Altai, M., et al. Feasibility of affibody-based bioorthogonal chemistry-mediated radionuclide pretargeting. J. Nucl. Med. 57 (2016), 431–436.
108. Honarvar, H., et al. Feasibility of affibody molecule-based pna-mediated radionuclide pretargeting of malignant tumors. Theranostics 6 (2016), 93–103.
109. Westerlund, K., et al. Design, preparation, and characterization of PNA-based hybridization probes for affibody-molecule-mediated pretargeting. Bioconjug. Chem. 26 (2015), 1724–1736.
110. Khaw, B.A., et al. Bispecific antibody complex pre-targeting and targeted delivery of polymer drug conjugates for imaging and therapy in dual human mammary cancer xenografts: targeted polymer drug conjugates for cancer diagnosis and therapy. Eur. J. Nucl. Med. Mol. Imaging 41 (2014), 1603–1616.
111. Bhattarai, P., et al. An in vitro demonstration of overcoming drug resistance in SKOV3 TR and MCF7 ADR with targeted delivery of polymer pro-drug conjugates. J. Drug Target. 25 (2017), 436–450.
112. Hagen, S., et al. Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme prodrug therapy. Sci. Rep., 4, 2014, 3759.
113. Koduvayur, S.P., et al. Targeted delivery of deoxycytidine kinase to Her2-positive cells enhances the efficacy of the nucleoside analog fludarabine. PLoS One, 11, 2016, e0157114.
114. Sandersjoo, L., et al. A new prodrug form of affibody molecules (pro-affibody) is selectively activated by cancer-associated proteases. Cell. Mol. Life Sci. 72 (2015), 1405–1415.
115. Nishimura, Y., et al. Affibody-displaying bio-nanocapsules effective in EGFR, typical biomarker, expressed in various cancer cells. Bioorg. Med. Chem. Lett. 27 (2017), 336–341.
116. Zhang, Y., et al. DNA-affibody nanoparticles for inhibiting breast cancer cells overexpressing HER2. Chem. Commun. (Camb) 53 (2017), 573–576.
117. Alavizadeh, S.H., Improved therapeutic activity of HER2 affibody-targeted cisplatin liposomes in HER2-expressing breast tumor models. Expert Opin. Drug Deliv. 13 (2016), 325–336.
118. Yang, H., et al. Nanobubble-affibody: novel ultrasound contrast agents for targeted molecular ultrasound imaging of tumor. Biomaterials 37 (2015), 279–288.
119. Lu, N., et al. Smart cancer cell targeting imaging and drug delivery system by systematically engineering periodic mesoporous organosilica nanoparticles. ACS Appl. Mater. Interfaces 8 (2016), 2985–2993.
120. Gujrati, V., et al. Bioengineered yeast-derived vacuoles with enhanced tissue-penetrating ability for targeted cancer therapy. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), 710–715.
121. Mohamed Suffian, I.F., Engineering hepatitis B virus core particles for targeting HER2 receptors in vitro and in vivo. Biomaterials 120 (2017), 126–138.
122. Narsireddy, A., et al. Photosensitizer and peptide-conjugated PAMAM dendrimer for targeted in vivo photodynamic therapy. Int. J. Nanomed. 10 (2015), 6865–6878.
123. Narsireddy, A., et al. Targeted in vivo photodynamic therapy with epidermal growth factor receptor-specific peptide linked nanoparticles. Int. J. Pharm. 471 (2014), 421–429.
124. Feng, G., et al. Multifunctional conjugated polymer nanoparticles for image-guided photodynamic and photothermal therapy. Small, 13, 2017.
125. Wallberg, H., et al. Affinity recovery of eight HER2-binding affibody variants using an anti-idiotypic affibody molecule as capture ligand. Protein Exp. Purif. 76 (2011), 127–135.
126. Eklund, M., et al. Anti-idiotypic protein domains selected from protein A-based affibody libraries. Proteins 48 (2002), 454–462.
127. Tippmann, S., et al. Affibody scaffolds improve sesquiterpene production in Saccharomyces cerevisiae. ACS Synth. Biol. 6 (2016), 19–28.
128. Jeong, H.-J., et al. One-pot construction of Quenchbodies using antibody-binding proteins. Anal. Methods 8 (2016), 7774–7779.
129. Moon, H., et al. Plug-and-playable fluorescent cell imaging modular toolkits using the bacterial superglue, SpyTag/SpyCatcher. Chem. Commun. (Camb) 52 (2016), 14051–14054.
130. Justino, C.I.L., et al. Analytical applications of affibodies. TrAC Trends Anal. Chem. 65 (2015), 73–82.
131. Gronwall, C., et al. Generation of affibody ligands binding interleukin-2 receptor alpha/CD25. Biotechnol. Appl. Biochem. 50 (2008), 97–112.
132. Sandström, K., et al. Inhibition of the CD28-CD80 co-stimulation signal by a CD28-binding affibody ligand developed by combinatorial protein engineering. Protein Eng. 16 (2003), 691–697.
133. Lundberg, E., et al. Selection and characterization of affibody ligands to the transcription factor c-Jun. Biotechnol. Appl. Biochem. 52 (2009), 17–27.
134. Nord, K., et al. Recombinant human factor VIII-specific affinity ligands selected from phage-displayed combinatorial libraries of protein A. Eur. J. Biochem. 268 (2001), 4269–4277.
135. Wikman, M., et al. Selection and characterization of an HIV-1 gp120-binding affibody ligand. Biotechnol. Appl. Biochem. 45 (2006), 93–105.
136. Ronnmark, J., et al. Human immunoglobulin A (IgA)-specific ligands from combinatorial engineering of protein A. Eur. J. Biochem. 269 (2002), 2647–2655.
137. Lindborg, M., et al. High-affinity binding to staphylococcal protein A by an engineered dimeric affibody molecule. Protein Eng. Des. Sel. 26 (2013), 635–644.
138. Hansson, M., et al. An in vitro selected binding protein (affibody) shows conformation-dependent recognition of the respiratory syncytial virus (RSV) G protein. Immunotechnology 4 (1999), 237–252.
139. Gunneriusson, E., Affinity maturation of a Taq DNA polymerase specific affibody by helix shuffling. Protein Eng. 12 (1999), 873–878.
140. Lofdahl, P.A., Nygren, P.A., Affinity maturation of a TNFalpha-binding affibody molecule by Darwinian survival selection. Biotechnol. Appl. Biochem. 55 (2010), 111–120.
141. Gronwall, C., et al. Affibody-mediated transferrin depletion for proteomics applications. Biotechnol. J. 2 (2007), 1389–1398.
142. Woldring, D.R., et al. A gradient of sitewise diversity promotes evolutionary fitness for binder discovery in a three-helix bundle protein scaffold. Biochemistry 56 (2017), 1656–1671.
143. Schlapschy, M., et al. PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins. Protein Eng. Des. Sel. 26 (2013), 489–501.
144. Podust, V.N., et al. Extension of in vivo half-life of biologically active molecules by XTEN protein polymers. J. Control. Release 240 (2016), 52–66.
145. Joubran, S., et al. Optimization of liganded polyethylenimine polyethylene glycol vector for nucleic acid delivery. Bioconjug. Chem. 25 (2014), 1644–1654.
146. Beuttler, J., et al. Targeting of epidermal growth factor receptor (EGFR)-expressing tumor cells with sterically stabilized affibody liposomes (SAL). Bioconjug. Chem. 20 (2009), 1201–1208.
147. Dong, D., et al. Human serum albumin and HER2-binding affibody fusion proteins for targeted delivery of fatty acid-modified molecules and therapy. Mol. Pharm. 13 (2016), 3370–3380.
148. Jonsson, A., et al. Engineering of a femtomolar affinity binding protein to human serum albumin. Protein Eng. Des. Sel. 21 (2008), 515–527.
149. Frejd, F.Y., Half-life extension by binding to albumin through an albumin binding domain. Kontermann, R., (eds.) Therapeutic Proteins: Strategies to Modulate their Plasma Half-Lives, 2012, Wiley-VCH Verlag GmbH & Co. KGaA, 269–283, 10.1002/9783527644827.ch14.
150. Andersen, J.T., et al. Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain. J. Biol. Chem. 286 (2011), 5234–5241.
151. Lindgren, J., et al. A GLP-1 receptor agonist conjugated to an albumin-binding domain for extended half-life. Biopolymers 102 (2014), 252–259.
152. Seijsing, J., et al. An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 17110–17115.